Rekha Sathyanarayana

Rekha Sathyanarayana is Vice President, Clinical Operations at Stealth BioTherapeutics. Rekha has more than 23 years of diverse therapeutic experience in pharmaceutical development, of which 12+ years have been serving in a key leadership position as Head of Clinical Operations, responsible for strategic oversight, budget and functional line management. Rekha has overseen global pivotal trials at Pharma, CRO and Biotech that culminated in bringing 6 commercial products to market. Prior to joining Stealth BioTherapeutics, Rekha was Vice President Clinical Operations at Titan Pharmaceuticals leading programs in Parkinson’s Disease and Opioid addition, including receiving a NIDA grant. Previously, she led her department through IND and BLA enabling programs at Revance Therapeutics. At Bavarian Nordic A/S, she led cancer vaccine program. At Depomed Inc, she was pivotal in securing NDA approvals of 3 commercial products. She also had increasing responsibilities at Neopath Inc, R2 Technologies, PPD Inc and Abbott Labs that yielded 510K & NDA approvals. Rekha holds a BS in Microbiology from Bangalore University and an advanced BS in Medical Technology from Northern Illinois University.